Literature DB >> 19182698

MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial.

Deborah Grady1, George F Sawaya, Karen C Johnson, William Koltun, Rachel Hess, Eric Vittinghoff, Margaret Kristof, Mary Tagliaferri, Isaac Cohen, Kristine E Ensrud.   

Abstract

OBJECTIVE: To determine the optimal dose, safety, and efficacy of an estrogen receptor beta selective Chinese herbal extract, menopausal formula 101 (MF101), for treating hot flushes.
METHODS: A randomized, blinded trial in 217 postmenopausal women with hot flushes randomized to 5 or 10 g/day of MF101 or placebo for 12 weeks.
RESULTS: The effects of 5 g/day of MF101 did not differ from those of placebo. After 12 weeks, the mean percent decrease in frequency of hot flushes in the 10 g/day group was 12.9% greater than that in the placebo group (P = 0.15), the median percent decrease was 11.7% greater than that in the placebo group (P = 0.05), and the proportion of women with at least a 50% reduction in hot flushes was 16.2% greater than that in the placebo group (P = 0.03).
CONCLUSIONS: Treatment with 10 g/day of MF101 reduces the frequency of hot flushes. Trials with higher doses are planned.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19182698     DOI: 10.1097/gme.0b013e31818e64dd

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  21 in total

Review 1.  Development of subtype-selective oestrogen receptor-based therapeutics.

Authors:  Stefan Nilsson; Konrad F Koehler; Jan-Åke Gustafsson
Journal:  Nat Rev Drug Discov       Date:  2011-09-16       Impact factor: 84.694

2.  Therapeutic significance of estrogen receptor β agonists in gliomas.

Authors:  Gangadhara R Sareddy; Binoj C Nair; Vijay K Gonugunta; Quan-guang Zhang; Andrew Brenner; Darrell W Brann; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Mol Cancer Ther       Date:  2012-03-21       Impact factor: 6.261

Review 3.  Minireview: Estrogen receptor-beta: mechanistic insights from recent studies.

Authors:  Bonnie J Deroo; Adrian V Buensuceso
Journal:  Mol Endocrinol       Date:  2010-04-02

4.  Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands.

Authors:  Erin K Shanle; John R Hawse; Wei Xu
Journal:  Biochem Pharmacol       Date:  2011-09-06       Impact factor: 5.858

Review 5.  Structural and Functional Diversity of Estrogen Receptor Ligands.

Authors:  Amjad Farooq
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

Review 6.  Cancer therapy using natural ligands that target estrogen receptor beta.

Authors:  Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Chin J Nat Med       Date:  2015-11

7.  Estrogen receptor beta-selective agonists stimulate calcium oscillations in human and mouse embryonic stem cell-derived neurons.

Authors:  Lili Zhang; Brigitte E Blackman; Marcus D Schonemann; Tatjana Zogovic-Kapsalis; Xiaoyu Pan; Mary Tagliaferri; Heather A Harris; Isaac Cohen; Renee A Reijo Pera; Synthia H Mellon; Richard I Weiner; Dale C Leitman
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

Review 8.  Molecular pathways: Estrogen pathway in colorectal cancer.

Authors:  Afsaneh Barzi; Annika Medea Lenz; Melissa J Labonte; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2013-08-21       Impact factor: 12.531

Review 9.  Estrogen receptor β in Alzheimer's disease: From mechanisms to therapeutics.

Authors:  Liqin Zhao; Sarah K Woody; Anindit Chhibber
Journal:  Ageing Res Rev       Date:  2015-08-22       Impact factor: 10.895

10.  Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists.

Authors:  Sreenivasan Paruthiyil; Aleksandra Cvoro; Xiaoyue Zhao; Zhijin Wu; Yunxia Sui; Richard E Staub; Scott Baggett; Candice B Herber; Chandi Griffin; Mary Tagliaferri; Heather A Harris; Isaac Cohen; Leonard F Bjeldanes; Terence P Speed; Fred Schaufele; Dale C Leitman
Journal:  PLoS One       Date:  2009-07-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.